期刊文献+

精准医疗与妇科肿瘤 被引量:6

原文传递
导出
摘要 继"人类基因组计划"(human genome project,HGP)之后,今年初,美国总统奥巴马宣布将从2016年财政预算中划拨2.15亿美元经费用于"精准医疗计划"(Precision Medicine Initiative),美国国立卫生研究院(www.nih.gov/presisionmedicnin)制定了详细的工作框架,这个框架旨在汇总数据、综合分析和发掘人类疾病的基本原理,并试图发现一系列个性化的疾病诊断和治疗的潜力分子,将基因组数据与临床数据有机的结合起来,使医生和患者迅速地了解和利用这些数据。
作者 昌晓红 崔恒
出处 《中国妇产科临床杂志》 CSCD 北大核心 2015年第5期385-387,共3页 Chinese Journal of Clinical Obstetrics and Gynecology
基金 首都医学发展基金(2139000007)
  • 相关文献

参考文献9

  • 1Gabai-Kapara E, LahadA, Kaufman B, etal. Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2. Proc Natl Acad Sci USA, 2014, 111 : 14205-14210.
  • 2Kummar S, Oza AM, Fleming GF, et al. Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer. Clin Cancer Res, 2015, 21: 1574-1582.
  • 3ColemanRL, SillMW, Bell-McGuinnK, etal.Aphase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/ Gynecologic Oncology Group study. Gynecol Oncol, 2015, 137: 386-391.
  • 4Zhen S, Bian LH, Chang LL, et al. Comparison of serum human epididymis protein 4 and carbohydrate antigen 125 as markers in ovarian cancer: A meta-analysis. Mol Clin Oncol, 2014, 2: 559-566.
  • 5Bluestone JA, Tang Q. Immunotherapy: making the case for pre cision medicine. Sci Transl Med, 2015, 7: 280ed3.
  • 6Korman AJ, Peggs KS, Allison JP. Checkpoint blockade in cancerimmunotherapy. Advlmmunol, 2006, 90: 297-339.
  • 7Lesokhin AM, Callahan MK, Postow MA, et al. On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation. Sci Transl Med., 2015, 7: 280srl.
  • 8Hamanishi J. Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer, ASCO Annual Meeting. 2014. Abstract# 5511 2014: http: //meetinglibrary. asco.org/ content/130814-144.
  • 9Robert C, Ribas A, Wolchok JD, et al. Anti-programmed- death-receptor- 1 treatment with pembrolizumab in ipilimumab- refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet, 2014, 384: 1109-1117.

同被引文献107

引证文献6

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部